Experimental Alzheimer's Drug That Fights a Tough-to-Target Protein Shows Promise at Slowing Cognitive Decline in a Clinical Trial

Recently FDA-approved treatments work to clear clumps of the protein amyloid beta in the brain. A drug that instead goes after tangles of the protein tau can yield similar cognitive outcomes, a new study suggests